What causes persistent changes in habits, personality, and behavior in a patient with a history of schizophrenia or schizoaffective disorder after quitting Invega Sustenna (paliperidone palmitate) injections?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: January 30, 2026View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Persistent Changes After Discontinuing Invega Sustenna

The persistent changes in habits, personality, and behavior you're experiencing after stopping Invega Sustenna (paliperidone palmitate) are most likely due to the underlying schizophrenia or schizoaffective disorder itself rather than permanent medication effects, as the illness naturally impacts cognitive functioning, insight, social functioning, and behavioral patterns even during periods of apparent stability. 1

Understanding What's Happening

The Illness Itself Causes These Changes

  • Schizophrenia and schizoaffective disorder inherently affect cognitive functioning, personality traits, insight, propensity to behavioral changes, and social/vocational functioning—these are core features of the illness, not medication side effects. 1

  • After approximately 10 years, the acute phases of schizophrenia tend to remit, leaving a residual state with varying disability, though recovery remains incomplete in approximately 80% of cases where patients have had more than one episode. 2

  • The illness can cause persistent changes in how you think, feel, and behave that may become more apparent after stopping medication because the medication was partially masking or managing these symptoms. 1

Why You Notice Changes After Stopping

  • You may be experiencing subclinical symptoms or early relapse signs that manifest as personality and behavioral changes rather than obvious psychotic symptoms. 1

  • The period of highest risk for relapse is in the first 8-12 weeks after medication discontinuation, but changes can persist much longer. 3

  • Approximately 65% of patients receiving placebo will relapse within 1 year of their acute psychotic phase, compared with only 30% receiving antipsychotics. 3

Medication Discontinuation Effects vs. Illness Progression

  • While antipsychotics can cause side effects during treatment (weight gain, sedation, movement disorders), these typically resolve after discontinuation—they don't cause permanent personality changes. 4, 5

  • The persistent changes you're experiencing are far more consistent with the natural course of inadequately treated schizophrenia/schizoaffective disorder than with permanent medication effects. 1, 2

  • Long-term follow-up studies demonstrate that only 2-5% of patients with early-onset schizophrenia achieve complete recovery, while the majority (74%) remain moderately to severely impaired even with treatment. 2

Critical Warning Signs

You Are at Extremely High Risk Right Now

  • Non-adherence is the single most powerful predictor of relapse, with a relapse rate five times higher among those who discontinue medication compared with those who continue treatment. 1, 3, 2

  • The changes in habits, personality, and behavior you're noticing may represent prodromal (early warning) symptoms of impending relapse rather than permanent changes. 1

What You Should Do Immediately

Resume Treatment Without Delay

  • You need to restart antipsychotic treatment immediately, ideally with a long-acting injectable formulation like Invega Sustenna to prevent future non-adherence. 1, 3

  • Guidelines specifically recommend LAI formulations for patients who have demonstrated non-adherence with recurrent relapses. 1, 3

  • The National Institute for Health and Clinical Excellence guidelines suggest LAI treatment plans where avoidance of covert non-adherence to the antipsychotic regimen is a clinical priority. 3

Expected Outcomes with Proper Treatment

  • Approximately one-third (33%) of patients with recurrent schizophrenia will obtain long-lasting symptom reduction with continuous treatment. 2

  • However, only 5% of patients with recurrent schizophrenia achieve complete recovery after multiple episodes. 2

  • The behavioral and personality changes you're experiencing may improve with treatment resumption, but some residual symptoms are common even with optimal treatment. 2

Common Pitfalls to Avoid

  • Do not assume these changes are permanent medication damage—this is almost certainly your underlying illness manifesting without adequate treatment. 1, 2

  • Do not attempt to manage this without professional psychiatric care, as the risk of full relapse with hospitalization, functional decline, and potential harm is extremely high. 1, 3

  • Do not rely on oral medications if you've already demonstrated non-adherence—studies indicate that both patients and clinicians overestimate the degree of adherence. 3

  • Do not underestimate the impact of relapse on your long-term functioning, as one or two relapses can have a major impact in diminishing academic, vocational, and social opportunities. 3

References

Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

Guideline

Maintenance Therapy Outcomes in Recurrent Schizophrenia

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2026

Guideline

Employment Fitness for Boat Crew Work in Schizophrenia Patients

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Related Questions

Should the dose of Invega (paliperidone) be increased in an adult patient with schizophrenia or schizoaffective disorder who developed less energy, increased depression, and anxiety after initial excessive energy on day 4 of treatment?
What is the best antipsychotic for treating schizoaffective disorder?
Can a patient taking Invega Trinza (paliperidone) 819 mg every 3 months use Invega (paliperidone) 6 mg Oral as a PRN (pro re nata) for breakthrough psychosis?
Can Invega (paliperidone) and Lamictal (lamotrigine) be taken together for the treatment of schizoaffective bipolar type?
Are there any interactions between Invega (paliperidone) and marijuana?
What is the management approach for a patient with a basilar skull fracture, bloody fluid from the ear, and bilateral or unilateral peri-orbital ecchymosis?
What is the appropriate treatment for an adult patient with no significant medical history, presenting with hypertriglyceridemia, cholesterol 184 mg/dL, HDL (High-Density Lipoprotein) 47 mg/dL, and LDL (Low-Density Lipoprotein) 82 mg/dL?
What should be done for a patient with a history of depression who is experiencing a decrease in response to Transcranial Magnetic Stimulation (TMS) treatment?
Is unopposed estradiol (estrogen) a proper treatment for menopause in an elderly postmenopausal woman with hypertension and a history of cardiovascular disease?
Do basilar skull fractures typically present with unilateral or bilateral peri-orbital (around the eye) ecchymosis (bruising)?
What is the best treatment approach for a patient with cervical facet pain?

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.